On February 17, 2021, Excision BioTherapeutics, a leading developer of potentially curative CRISPR anti-viral therapies to improve patient lives, announced the completion of a $60 million financing. The proceeds will be used to advance Excision’s lead candidate, EBT-101, into a Phase 1/2 clinical trial in patients with chronic HIV infection. The financing will also support preclinical programs including EBT-103 targeting JC Virus for Progressive Multifocal Leukoencephalopathy (PML), EBT-104 for Herpes Simplex Virus, and EBT-107 for Hepatitis B.

The financing round was led by GreatPoint Ventures with support from existing investor ARTIS Ventures. New investors include Adjuvant Capital, Norwest Venture Partners, Anzu Partners, Cota Capital, WRVI Capital, IndusAge Partners, Loreda Holdings, and Olive Tree Capital.

The Wilson Sonsini Goodrich & Rosati team that advised Excision BioTherapeutics on IP matters related to the transaction includes patent attorneys , Gregory Mitchell, Michael Hostetler, and Brett Zirkle and technology transactions attorneys Lauren Wardle and Miranda Biven.

For more information, please see Excision BioTherapeutics' press release.